Volpara and image analysis developer ScreenPoint Medical have signed an MOU which will see the two companies seek to bring ScreenPoint’s artificial intelligence–based Transpara detection and decision support software to Volpara users globally.
ScreenPoint Medical, based in the Netherlands, develops image analysis technology for the automated reading of mammograms and digital breast tomosynthesis exams, using big data, deep learning and artificial intelligence.
Subject to further discussions under the MOU, Volpara will deliver ScreenPoint’s AI-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem.
ScreenPoint’s Transpara recently received 510(k) clearance from the US Food and Drug Administration (FDA) to assist radiologists with the reading of screening mammograms; this is a very complementary product to Volpara’s offering and should add further to the ARPU.
Volpara Chief Executive Dr Ralph Highnam said that adding an important product like Transpara Decision Support to Volpara’s product offerings is a perfect step for Volpara. “It enriches our offering to breast imaging centres in the US and abroad, and expands the VolparaEnterprise ecosystem as we build a platform for delivering well-curated AI and other software applications for our customers,” Dr Highnam said.
